STOCK TITAN

[Form 3] Medicus Pharma Ltd. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) Form 3: Newly designated director Cathy McMorris Rodgers has filed her initial beneficial ownership report. Her sole holding is a stock option for 25,000 common shares granted on 22-Jul-2025 with a $3.08 exercise price. The option vests quarterly in four equal tranches over one year and expires on 22-Jul-2030. No common shares or additional derivatives are listed. The filing is made by a single reporting person and includes a power-of-attorney executed by Raza Bokhari on her behalf.

Medicus Pharma Ltd. (MDCX) Modulo 3: La nuova direttrice designata Cathy McMorris Rodgers ha presentato il suo rapporto iniziale di proprietà effettiva. La sua unica partecipazione consiste in un opzione su azioni per 25.000 azioni ordinarie concessa il 22 luglio 2025 con un prezzo di esercizio di 3,08 USD. L'opzione matura trimestralmente in quattro tranche uguali nell'arco di un anno e scade il 22 luglio 2030. Non sono elencate azioni ordinarie o altri derivati aggiuntivi. La dichiarazione è effettuata da una sola persona segnalante e include una procura eseguita da Raza Bokhari per suo conto.

Medicus Pharma Ltd. (MDCX) Formulario 3: La nueva directora designada, Cathy McMorris Rodgers, ha presentado su informe inicial de propiedad beneficiaria. Su única participación es una opción sobre acciones para 25,000 acciones ordinarias otorgada el 22 de julio de 2025 con un precio de ejercicio de $3.08. La opción se consolida trimestralmente en cuatro tramos iguales durante un año y expira el 22 de julio de 2030. No se listan acciones ordinarias ni derivados adicionales. La presentación la realiza una sola persona informante e incluye un poder notarial ejecutado por Raza Bokhari en su nombre.

Medicus Pharma Ltd. (MDCX) 양식 3: 새로 지정된 이사인 Cathy McMorris Rodgers가 초기 실소유 보고서를 제출했습니다. 그녀의 단독 보유 내역은 2025년 7월 22일 부여된 25,000 보통주에 대한 스톡 옵션이며, 행사가격은 3.08달러입니다. 이 옵션은 1년 동안 4개의 동일한 분할로 분기별로 권리가 부여되며, 2030년 7월 22일에 만료됩니다. 보통주나 추가 파생상품은 기재되어 있지 않습니다. 이 제출은 단일 보고자가 수행했으며, Raza Bokhari가 그녀를 대신해 실행한 위임장이 포함되어 있습니다.

Medicus Pharma Ltd. (MDCX) Formulaire 3 : La nouvelle administratrice désignée, Cathy McMorris Rodgers, a déposé son rapport initial de propriété bénéficiaire. Sa seule détention est une option d'achat portant sur 25 000 actions ordinaires accordée le 22 juillet 2025 avec un prix d'exercice de 3,08 $. L'option est acquise trimestriellement en quatre tranches égales sur une année et expire le 22 juillet 2030. Aucune action ordinaire ni dérivé supplémentaire n'est listé. Le dépôt est effectué par une seule personne déclarant et comprend une procuration signée par Raza Bokhari en son nom.

Medicus Pharma Ltd. (MDCX) Formular 3: Die neu ernannte Direktorin Cathy McMorris Rodgers hat ihren ersten Bericht über wirtschaftliches Eigentum eingereicht. Ihr einziges Beteiligungsrecht ist eine Aktienoption für 25.000 Stammaktien, die am 22. Juli 2025 mit einem Ausübungspreis von 3,08 USD gewährt wurde. Die Option wird vierteljährlich in vier gleichen Tranchen über ein Jahr hinweg ausgeübt und läuft am 22. Juli 2030 ab. Es sind keine Stammaktien oder weitere Derivate aufgeführt. Die Meldung erfolgt durch eine einzelne meldende Person und beinhaltet eine von Raza Bokhari in ihrem Namen ausgeführte Vollmacht.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine Form 3; director discloses 25k options at $3.08—minimal immediate valuation impact.

This filing merely establishes insider reporting compliance for a new board member. The option grant is typical director compensation, representing potential dilution of 25,000 shares, which is likely immaterial relative to Medicus Pharma’s outstanding share count (not provided here). No open-market purchases or sales were reported, so there is no direct signal on sentiment or near-term cash outlay. Overall, the disclosure is neutral for investors.

TL;DR: Filing improves governance transparency; aligns new director incentives via time-based vesting.

The quarterly vesting schedule over one year ties the director’s upside to short-term execution, while the five-year term (2025-2030) maintains longer-term alignment. Inclusion of a power-of-attorney ensures timely future Section 16 reporting. Although standard, such disclosures support best practices and may marginally enhance investor confidence.

Medicus Pharma Ltd. (MDCX) Modulo 3: La nuova direttrice designata Cathy McMorris Rodgers ha presentato il suo rapporto iniziale di proprietà effettiva. La sua unica partecipazione consiste in un opzione su azioni per 25.000 azioni ordinarie concessa il 22 luglio 2025 con un prezzo di esercizio di 3,08 USD. L'opzione matura trimestralmente in quattro tranche uguali nell'arco di un anno e scade il 22 luglio 2030. Non sono elencate azioni ordinarie o altri derivati aggiuntivi. La dichiarazione è effettuata da una sola persona segnalante e include una procura eseguita da Raza Bokhari per suo conto.

Medicus Pharma Ltd. (MDCX) Formulario 3: La nueva directora designada, Cathy McMorris Rodgers, ha presentado su informe inicial de propiedad beneficiaria. Su única participación es una opción sobre acciones para 25,000 acciones ordinarias otorgada el 22 de julio de 2025 con un precio de ejercicio de $3.08. La opción se consolida trimestralmente en cuatro tramos iguales durante un año y expira el 22 de julio de 2030. No se listan acciones ordinarias ni derivados adicionales. La presentación la realiza una sola persona informante e incluye un poder notarial ejecutado por Raza Bokhari en su nombre.

Medicus Pharma Ltd. (MDCX) 양식 3: 새로 지정된 이사인 Cathy McMorris Rodgers가 초기 실소유 보고서를 제출했습니다. 그녀의 단독 보유 내역은 2025년 7월 22일 부여된 25,000 보통주에 대한 스톡 옵션이며, 행사가격은 3.08달러입니다. 이 옵션은 1년 동안 4개의 동일한 분할로 분기별로 권리가 부여되며, 2030년 7월 22일에 만료됩니다. 보통주나 추가 파생상품은 기재되어 있지 않습니다. 이 제출은 단일 보고자가 수행했으며, Raza Bokhari가 그녀를 대신해 실행한 위임장이 포함되어 있습니다.

Medicus Pharma Ltd. (MDCX) Formulaire 3 : La nouvelle administratrice désignée, Cathy McMorris Rodgers, a déposé son rapport initial de propriété bénéficiaire. Sa seule détention est une option d'achat portant sur 25 000 actions ordinaires accordée le 22 juillet 2025 avec un prix d'exercice de 3,08 $. L'option est acquise trimestriellement en quatre tranches égales sur une année et expire le 22 juillet 2030. Aucune action ordinaire ni dérivé supplémentaire n'est listé. Le dépôt est effectué par une seule personne déclarant et comprend une procuration signée par Raza Bokhari en son nom.

Medicus Pharma Ltd. (MDCX) Formular 3: Die neu ernannte Direktorin Cathy McMorris Rodgers hat ihren ersten Bericht über wirtschaftliches Eigentum eingereicht. Ihr einziges Beteiligungsrecht ist eine Aktienoption für 25.000 Stammaktien, die am 22. Juli 2025 mit einem Ausübungspreis von 3,08 USD gewährt wurde. Die Option wird vierteljährlich in vier gleichen Tranchen über ein Jahr hinweg ausgeübt und läuft am 22. Juli 2030 ab. Es sind keine Stammaktien oder weitere Derivate aufgeführt. Die Meldung erfolgt durch eine einzelne meldende Person und beinhaltet eine von Raza Bokhari in ihrem Namen ausgeführte Vollmacht.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Rodgers Cathy McMorris

(Last) (First) (Middle)
300 CONSHOHOCKEN STATE ROAD
SUITE 200

(Street)
W. CONSHOHOCKEN PA 19428

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
07/22/2025
3. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 07/22/2030 Common Shares 25,000 $3.08 D
Explanation of Responses:
1. The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Remarks:
Exhibit List - Exhibit 24.1 - Power of Attorney
/s/ Raza Bokhari, as Attorney-in-Fact, for Cathy McMorris Rodgers 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting person in Medicus Pharma (MDCX) Form 3?

The reporting person is Cathy McMorris Rodgers, listed as a director of Medicus Pharma.

How many stock options does Cathy McMorris Rodgers report owning in MDCX?

She reports 25,000 stock options for Medicus Pharma common shares.

What is the exercise price and expiration date of the reported options?

The options are exercisable at $3.08 and expire on 22-Jul-2030.

When do the director’s options vest?

They vest quarterly in four equal installments over the year following the 22-Jul-2025 grant date.

Is this Form 3 filed by a single reporting person or a group?

The form is filed by one reporting person only.

What is the purpose of SEC Form 3?

Form 3 is the initial statement of beneficial ownership required of insiders (e.g., directors) under Section 16(a) of the Exchange Act.
Medicus Pharma Ltd

NASDAQ:MDCX

MDCX Rankings

MDCX Latest News

MDCX Latest SEC Filings

MDCX Stock Data

41.06M
8.82M
Pharmaceutical Preparations
W. CONSHOHOCKEN